September 25, 2015 9:44 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Bellerophon Therapeutics Inc (NASDAQ: BLPH) shares surged 38.71 percent to $5.16 after the company reported positive data from an interim analysis of its Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension.
Cirrus Logic, Inc. (NASDAQ: CRUS) shares rose 12.05 percent to $30.40.
Jabil Circuit, Inc. (NYSE: JBL) shares gained 10.81 percent to $21.63 after the company reported better-than-expected results for its fiscal fourth quarter and issued a strong forecast for the current quarter.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Nike Inc (NYSE: NKE) shares jumped 7.52 percent to $123.42 after the company reported stronger-than-expected results for its fiscal first quarter.
Sientra Inc (NASDAQ: SIEN) shares surged 6.19 percent to $10.30 after dropping 52.87 percent on Thursday.
Marvell Technology Group Ltd. (NASDAQ: MRVL) rose 5.32 percent to $9.51 after the company reported significant restructuring of mobile platform business. The company plans to cut its global workforce by 17 percent.
Arrowhead Research Corp (NASDAQ: ARWR) shares surged 5.01 percent to $7.55. Arrowhead Research shares jumped 6.68 percent Thursday following announcement of results of ARC-520 Hep B study.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.